Dr. Andreas Menrad - Algeta
Norwegian firm Algeta has appointed Dr. Andreas Menrad to the role of Chief Scientific Officer, responsible for developing and executing the Company’s research strategy, including its Targeted Thorium Conjugate (TTC) platform.
Menrad has over 20 years of experience in the industry and has worked previously for Genzyme in Cambridge, UK.
“Andreas brings a wealth of complementary skills and experience to Algeta from his successful career in therapeutic research and development,” said CEO Andrew kay. “We are confident that, in this key strategic leadership role, he will guide the development and direction of our research team as we seek to create a pipeline of development candidates.”
The firm has also announced Dr Thomas Ramdahl, the Company’s Executive Vice President, will become Algeta’s Chief Operating Officer.